Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT28NV
|
|||
| Drug Name |
AVR-RD-01
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Fabry disease [ICD-11: 5C56.01; ICD-9: 272.7] | Phase 1/2 | [1] | |
| Company |
AVROBIO
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-galactosidase A (GLA) | Target Info | . | [2] |
| KEGG Pathway | Galactose metabolism | |||
| Glycerolipid metabolism | ||||
| Sphingolipid metabolism | ||||
| Glycosphingolipid biosynthesis - globo series | ||||
| Lysosome | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Galactose Metabolism | ||||
| Reactome | Glycosphingolipid metabolism | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03454893) FAB- GT Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Avrobio. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.